Clinical Trials Logo

Recurrent Endometrial Cancer clinical trials

View clinical trials related to Recurrent Endometrial Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05798611 Recruiting - Clinical trials for Advanced Solid Tumor

Study of ART0380 in Patients With Biologically Selected Solid Tumors

ARTIST
Start date: September 6, 2023
Phase: Phase 2
Study type: Interventional

This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).

NCT ID: NCT05263492 Recruiting - Endometrial Cancer Clinical Trials

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Start date: April 1, 2022
Phase: Phase 2
Study type: Interventional

Determine the efficacy of the combination of lenvatinib and pembrolizumab in Black participants

NCT ID: NCT03564340 Recruiting - Clinical trials for Recurrent Ovarian Cancer

Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Start date: May 21, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to: - Learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus - The study will also look at the levels of REGN4018 and/or cemiplimab in your body and measure how well your body can remove the study drug(s). This is called pharmacokinetics - The study will also look at any signs that REGN4018 alone or with cemiplimab can treat recurrent advanced ovarian cancer or cancer of the uterus - To find out how safe and tolerable the sarilumab pretreatment is, in combination with REGN4018 and cemiplimab